Why AbbVie Stock Trounced the Market in 2025

Core Viewpoint - AbbVie had a remarkable year in 2025, with its stock price increasing by nearly 29%, outperforming the S&P 500 index's 16% gain, driven by strong sales from its leading drugs and strategic acquisitions [1][2]. Group 1: Sales Performance - AbbVie successfully navigated the patent cliff of its popular drug Humira, with its two leading drugs, Skyrizi and Rinvoq, generating a combined $24 billion in sales during the year, surpassing the total revenue of most pharmaceutical companies [2][3]. - The immunology segment, which includes Humira, Skyrizi, and Rinvoq, is not the only growth driver; the neuroscience segment also performed well, with Vyralar achieving a nearly 7% year-over-year sales increase to $931 million in Q3 2025 [4]. Group 2: Strategic Growth Initiatives - AbbVie actively pursued acquisitions and collaborations to sustain growth, including the notable acquisition of Capstan Therapeutics, which focuses on next-generation autoimmune therapies [5][6]. - The company entered into a partnership with China's Simcere Zaiming for an investigational multiple myeloma drug, highlighting its commitment to expanding its pipeline through strategic alliances [6]. Group 3: Future Outlook - Although AbbVie has not yet released its Q4 and full-year 2025 results, both the company and analysts anticipate an annual revenue increase of over 8% to nearly $61 billion, despite a projected 2% dip in per-share profitability to $9.93 [7].